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Background: Recent reports indicate an ongoing BCG shortage that may inﬂuence immunisation practice.
This study aimed to determine current availability of BCG vaccine across Europe, and implications on
immunisation practices and policies in Europe.
Methods: Web-based survey among Paediatric Tuberculosis Network European Trials Group (ptbnet)
members, between May and October 2015.
Results: Twenty individuals from 13 European countries participated. Ongoing shortages were reported
in eight countries routinely using BCG (8/11, 73%). As a consequence of the shortage, BCG was not given
as completely unavailable in some countries (2/8, 25%), was given only whenever available (1/8, 13%), or
only in certain regions of the country (1/8, 13%). Strategies reported to reduce loss of immunisation were
administration to selected high-risk individuals (2/8, 25%), or cohorting vaccinees on speciﬁc days to
maximise the use of multi-dose vials (3/8, 38%). Authorities in two countries each were considering a
change of manufacturer/supplier (2/8, 25%).
Conclusions: The BCG shortage in Europe leads to signiﬁcant changes in immunisation policies including
changes of BCG vaccine strain and manufacturer. In addition, infants and children eligible for immuni-
sation are at risk of not receiving BCG. To ensure necessary BCG immunisations, collaboration between
national health agencies and vaccine manufacturers is crucial.
© 2016 Elsevier Ltd. All rights reserved.lmette-Guerin; ECDC, European Centre for Disease Prevention and Control (the); TB, tuberculosis; MDR, multidrug-
ropean Trials group (the); SSI, Statens Serum Institut (the); UNICEF, United Nations Children's Emergency Fund (the);
ve drug resistance.
ey was published as an abstract at the 34th Annual Meeting of the European Society for Paediatric Infectious Diseases,
ediatric Pharmacology, University Children's Hospital Basel, Spitalstrasse 33, CH-4031 Basel, Switzerland.
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Globally, tuberculosis (TB) is one of the most important infec-
tious diseases and children are especially vulnerable [1,2].
Compared to adults, children infected with Mycobacterium tuber-
culosis are more likely to develop active TB disease within a short
period of time. In 2014, an estimated 1 million new TB cases and
140.000 TB deaths occurred globally among children below 15
years of age [1]. Although the overall TB incidence in Europe is
decreasing, TB remains a major public health concern [3]. The
World Health Organization (WHO) estimates that there were
31.000 new TB cases among children in the European Region in
2014, of which only 32% were reported [1]. In many countries, the
majority of TB cases are foreign-origin, and with the current
migration in Europe this will affect epidemiology in low incidence
TB countries [3,4]. Furthermore, with the emergence of multidrug-
resistant (MDR) and extensively drug-resistant (XDR) TB, treatment
is becoming increasingly challenging, placing further emphasis on
the importance of prevention [3].
Infant Bacille Calmette-Guerin (BCG) immunisation prevents
severe and disseminated TB in children, and may also protect
against latent TB infection [5,6]. The protective efﬁcacy of BCG
against drug-susceptible and MDR TB is likely similar and, there-
fore, BCG immunisation has been suggested as a preventative
measure for individuals exposed to MDR-TB [7]. BCG is one of the
most commonly used vaccines globally, with approximately 90% of
children covered worldwide and over 120 million individuals
vaccinated annually [8,9]. Vaccine coverage is however not uniform
worldwide since many low TB incidence countries do not offer BCG
at all or only for selected high-risk groups, while some high TB
incidence countries including Papua New Guinea, Somalia and the
Ukraine have coverage rates below 70% [10]. In high TB incidence
countries, BCG immunisation is a cost-effective intervention and an
essential part of TB control and prevention particularly in young
children [5]. In addition, BCG immunisation is known to have a
number of non-speciﬁc or heterologous effects, including reducing
all-cause mortality in resource limited countries and inﬂuencing
the immune response to other routine immunisations [11,12].
Currently, three BCG vaccine strains are in large-scale produc-
tion (BCG Denmark, BCG Russia and BCG Japan) which are pro-
duced by ﬁveWHO prequaliﬁed vaccine manufacturers in Bulgaria,
Denmark, India and Japan [13,14]. In Europe, BCG Denmark has
been themost commonly used BCG vaccine strain in the last decade
[15,16].
BCG supply and demand has been inﬂuenced by a decrease in
manufacturers worldwide together with an increased global de-
mand, likely as a result of rising birth rates and improved immu-
nisation coverage. In 2014, the demand increased by more than 20
million doses, as a result of unmet demand carry-over from the
previous year and incremental demand from some large countries
in the Middle East and South East Asia, and it is estimated to in-
crease further by an annual 10 million doses [8]. In addition to this,
since 2013, a reduced production capacity of two manufacturers,
the Statens Serum Institut (SSI) in Denmark and the Serum Institute
of India, further affects annual global BCG availability [17]. Although
some manufacturers were able to increase their production, the
overall BCG availability fell by 6 million doses [8]. In fact, the United
Nations Children's Emergency Fund (UNICEF) estimated that in
2014 the global BCG production fell short by over 20 million doses,
and that in 2015 the unmet demand carry-over together with
growing demand and continuing production shortage may result in
a deﬁcit of over 70 million doses [8].
This shortage is likely to affect BCG immunisation practices and
coverage in Europe, as universal or selective immunisation is a part
of TB prevention in at least 27 European countries [15]. Wetherefore conducted a survey to determine current availability of
BCG vaccine across Europe, and describe the implications on
immunisation practices and policies.
2. Methods
We conducted a web-based survey among Paediatric Tubercu-
losis Network European Trials Group (ptbnet) members between
May 2015 and October 2015. Ptbnet comprises clinicians, microbi-
ologists, epidemiologists and researches with a special interest in
paediatric TB [18,19]. At the time of the survey, ptbnet had a total of
117 members in 25 European countries. Members were invited by
e-mail to participate in the survey, which included 16 questions on
the participant's demographics, use of BCG vaccine, BCG availabil-
ity, and consequences of possible shortage. Answers were collected
through Google Docs software (Google Inc., Mountain View, CA, US)
and/or Word questionnaire (Microsoft Corporation, Redmond, WA,
US). Participants were allowed to reply to all or only some of the
questions. The full questionnaire and the response rates to each
question are shown in the supplementary data. Two reminders
were sent: to all members in September 2015, and only to the
designated ptbnet representative of member countries in October
2015. In instances where responses were unclear or conﬂicting,
these were clariﬁed through email until January 2016. The ﬁnal
data were collated into and analysed using Excel (Version 2011,
Microsoft Corporation, Redmond, WA, US).
3. Results
Twenty individuals (20/117, 17%) from 13 European countries
(13/25, 52%) participated (Table 1). Respondents were based in
Austria, Belgium, Bulgaria, Croatia, Finland, Germany, Greece, Italy,
Slovenia, Spain, Sweden, Switzerland and the United Kingdom.
Respondents from eleven countries reported using BCG as part
of their national immunisation programme (11/13, 85%). The most
commonly reported vaccine strain used was BCG Denmark SSI 1331
(10/11, 91%). In addition, BCG Russia Bulbio Soﬁa was used, in
Bulgaria (1/11, 9%), where it is manufactured. BCG was reported to
be imported in most countries (10/11, 91%), with the exception of
Bulgaria, where it was reported to be produced nationally (1/11,
9%). Respondents reported that BCG was distributed by govern-
ment agencies or departments of health in most countries (5/7,
71%); in two countries, private companies were reported to be
national distributors - Econophar (Kortenberg, Belgium) and Pro
Farma AG (Baar, Switzerland). Data regarding the total number of
doses imported in 2014 were only available from two countries and
therefore not further analysed.
Speciﬁc national BCG immunization policies that were reported
included selective newborn immunization (5/11, 45%), selective
immunisation at a later age (3/11, 27%), or both (1/11, 9%), and
universal newborn immunisation (2/11, 18%). BCG immunisations
were reported to take place in maternity hospitals (3/11, 27%),
community health centre in primary care (3/11, 27%), primary
school (1/11, 9%), or all of these/multiple places (4/11, 36%).
A current BCG shortage was reported by respondents from eight
countries (8/11, 73%). In addition, a respondent from Croatia re-
ported a recent shortage that lasted less than a month; the
respondent stated that unmet carry-over immunisations took place
when the shortage had resolved. All affected countries were using
BCG Denmark. Responses concerning the onset of the shortage
varied and were sometimes conﬂicting; most respondents reported
that the shortage had started at some point from 2013 onwards.
Changes in BCG immunisation practices or policies were re-
ported by respondents from seven countries (7/8, 86%) (Table 2).
Members from Belgium and Italy reported a discontinuation of
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A. Kontturi et al. / Tuberculosis 101 (2016) 125e129 127immunisations as a result of BCG being entirely unavailable; in
Greece, BCG was reported to be given whenever available. In
Spain, BCG was reported to be available only in certain regions of
the country and, due to the shortage, given only to selected high-
risk individuals. Members from Finland, Sweden and the United
Kingdom reported cohorting vaccinees on speciﬁc days to use as
many doses from multi-dose vials as possible. One respondent
from the United Kingdom also reported that due to the shortage
BCG was only given to selected high-risk individuals. Switching
manufacturer and BCG strain were reported to be under consid-
eration in Belgium and Finland. A respondent from Sweden re-
ported that national data about the BCG shortage was being
collected. Out of the eight countries in which a BCG shortage was
reported, ﬁve reported that national BCG stockpiling was not
taking place (5/8, 63%), two reported that stockpiling was done (2/
8, 25%), and one did not respond to this question. Public national
information about the BCG shortage was reported to be available
in ﬁve countries (5/8, 63%), and unavailable in three countries (3/
8, 38%).
Shortage of BCG for bladder cancer treatment was reported by
respondents from two countries (2/11, 18%) and nine respondents
had no personal knowledge on this matter.
4. Discussion
Our results show that the ongoing global BCG vaccine shortage
has signiﬁcant consequences on immunisation practice in Europe.
The survey identiﬁed BCG shortages in eight European countries,
all of which were using BCG Denmark produced by SSI. A survey
conducted in 2013 showed that 24 out of 31 countries in the Eu-
ropean region were using BCG Denmark, and that at least 3 out of
the 18 high priority countries in the ﬁght against TB, as deﬁned by
the European Centre for Disease Prevention and Control (ECDC),
were using BCG Denmark [3,15]. Therefore, it is likely that the
limited supply of BCG Denmark affects also further countries not
captured in our survey. Among the countries captured in our
survey, only Bulgaria is classiﬁed as a high priority country in the
ﬁght against TB [3]. Bulgaria uses a nationally produced BCG
vaccine, and no shortage was reported from this country.
Our results also highlight that in many European countries on-
going BCG shortages have resulted in changes in immunisation
practices and policies. One approach is optimising the use of
multidose BCG vaccine vials by centralising and cohorting BCG
immunisations to reduce vaccine loss, and there is some data to
support that this may be effective. Unpublished data from Finland
suggest that centralising immunisations and giving BCG only on
speciﬁc dates using multidose vials resulted in halved vaccine
consumption (personal communication from Pertti Sormunen,
Director of Pharmaceutical Wholesale, National Institute for
Health and Welfare, Finland, April 19, 2016). However, a report
from Australia where a similar approach was used, estimated
vaccine wastage to be around 75% [20].Table 1
Demographic details of participants and summary of BCG use and shortage.
n %
Participants working at 20 100
Paediatric hospital 16 80
General hospital 3 15
Outpatient Tb specialised clinic 1 5
Countries 13 100
Not routinely using BCG (Austria, Germany) 2 10
No current shortage (Bulgaria, Slovenia, Croatia*) 3 15
Current shortage (Belgium, Finland, Greece, Italy,
Spain, Sweden, Switzerland, United Kingdom)
8 75
* Reported a recent shortage prior to the survey being conducted. Ta
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A. Kontturi et al. / Tuberculosis 101 (2016) 125e129128Another option to address the ongoing shortage is changing the
BCG vaccine manufacturer. In our survey, authorities in two coun-
tries (Belgium and Finland) were reported to be considering an
alternative manufacturer. As of April 2016, two countries captured
in the survey (Finland and Sweden) have changed themanufacturer
and are now using BCG-Japan (personal communication from Pertti
Sormunen, Director of Pharmaceutical Wholesale, National Insti-
tute for Health and Welfare, Finland, April 19, 2016) [21]. Further-
more, other countries, including France and Australia, have
temporarily replaced BCG Denmark with BCG Brazil manufactured
by Biomed Lublin in Poland [22,23]. This decision is somewhat
surprising as there is limited information on safety and protective
efﬁcacy of this BCG vaccine strain as it accounts for only a very small
proportion of BCG vaccine strains used globally [24]. BCG Poland is
a descendant of BCG Brazil (frequently called BCG Moreau or BCG
Rio de Janeiro) which has been used in Poland exclusively since
1955 and has been shown to be genetically different to its parent
strain [24]. Recent update from Public Health England reports that
the shortage is on-going [25] Considering the ongoing BCG
Denmark vaccine delivery delays, it appears likely that further
countries in Europe and globally will change to another BCG
manufacturer, resulting in a change of the BCG vaccine strain used
in their national immunisation programmes.
Importantly, changes in the BCG vaccine strains may have sig-
niﬁcant consequences. Different BCG vaccine strains have been
shown to inﬂuence the immune response and protection against TB
[9,14,26]. Recent evidence from a study comparing the genomes
and transcriptomes of several BCG vaccine strains showed an in-
crease in expression of ribosomal proteins in some strains which
may be responsible for increased immunogenicity and better pro-
tection against TB [27]. However, it currently remains unclear
which BCG vaccine strain offers the best protective efﬁcacy, and
consequently any change might affect protection on a population
level. In addition, previous reports have shown that changes in the
BCG vaccine strain can be associated with an increased incidence of
BCG-associated adverse events (AEs). For instance, in 2002 Finland
changed from BCG Glaxo to BCG Denmark, as the production of the
former was discontinued. In the subsequent two years the inci-
dence of BCG-associated AEs increased considerably, which, in
combination with a decreasing TB incidence, ultimately led to
discontinuation of universal BCG immunisation in Finland in 2006
[28,29]. Similarly, a change from BCG Connaught to BCG Denmark
in Australia in 2012 led to, when administered doses were taken
into account, an estimated increased incidence of BCG-induced
abscesses and lymphadenitis [20]. AEs related to immunisations
cause concern in both healthcare professionals and the general
public, potentially impacting the general attitude on immunisa-
tions and thereby inﬂuencing coverage rates. Thus, monitoring
protective efﬁcacy and AEs after a BCG vaccine strain change is of
utmost importance.
The key limitations of this survey are the relatively small
number of participants, and the fact that we were unable to obtain
data from several European countries. In addition, the majority of
participants were based in specialised paediatric institutions, and
the data may therefore not be representative of the situation in
regional hospitals or at the private practice level. As the ptbnet is
mainly a European network we were unable to collect data on BCG
vaccine shortage outside Europe, where the impact is likely to be
considerably greater. However, a report from the WHO Child TB
Subgroup meeting in December 2015 stated that critical BCG vac-
cine shortages were affecting many countries worldwide [17].
It appears obvious that the problems related to the ongoing BCG
vaccine shortages cannot be solved by changing the vaccine
manufacturer, as this approach simply shifts the demand to another
manufacturer. It is therefore important that supranational healthorganisations, such as UNICEF, WHO and ECDC, engage with vac-
cine manufacturers to jointly devise mechanisms that ensure a
stable BCG vaccine supply that meets global demand. Notably, in
December 2015 UNICEF reported having increased orders with
three manufacturers amounting to an additional 38.3 million BCG
doses in 2015, which still left an estimated deﬁcit of 16.5 million
doses that year [30]. To our knowledge there is currently no speciﬁc
national or global assessment of the impact of this deﬁcit on
childhood TB, and such an assessment should be conducted by
either WHO or UNICEF based on TB notiﬁcation rates in the next
few years. In addition, the communication betweenmanufacturers,
national public health agencies and end users of the BCG vaccine
requires improvements so that the immunisation services can
adapt timely in the event of future shortages.
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